Stability and sterility of enoxaparin 8 mg/mL subcutaneous injectable solution

Brady S. Moffett, Kimberly Dinh, Jennifer Placencia, Gregory Pelkey, Shiu Ki Rocky Hui, Jun Teruya

Research output: Contribution to journalArticlepeer-review

3 Scopus citations


BACKGROUND: Enoxaparin is often diluted to accurately deliver doses to neonatal and infant patients. Current recommendations for dilutions may not be adequate for the smallest patients. METHODS: Review of dosing at our institution occurred, and an 8 mg/mL concentration of enoxaparin was chosen. A concentration of 8 mg/mL was compounded by diluting 0.4 mL of enoxaparin (100 mg/mL) into 4.6 mL of sterile water for injection into an empty sterile vial. Four syringes of the 8 mg/mL concentration were prepared by 5 technicians (20 total syringes). Stability and sterility testing occurred a 0, 7, 14, and 30 days. One-way repeated-measures analysis of variance was used to detect significant differences in Anti–Factor Xa concentrations at the testing time points. RESULTS: The dilution of enoxaparin was sterile at 30 days but exhibited significant degradation at the 30- day point (p < 0.05). CONCLUSION: A dilution of enoxaparin 8 mg/mL is stable and sterile for 14 days refrigerated but is not stable at 30 days.

Original languageEnglish (US)
Pages (from-to)322-326
Number of pages5
JournalJournal of Pediatric Pharmacology and Therapeutics
Issue number4
StatePublished - Jul 1 2016


  • Anti–factor xa concentrations
  • Enoxaparin
  • Low molecular weight heparin
  • Neonates
  • Stability
  • Sterility

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Pharmacology (medical)


Dive into the research topics of 'Stability and sterility of enoxaparin 8 mg/mL subcutaneous injectable solution'. Together they form a unique fingerprint.

Cite this